Dr. Chris Barbieri is a urologic surgeon whose long-term goal is the definition of distinct molecular classes of prostate cancer, functional modeling of these subtypes to define drivers and therapeutic vulnerability, and translation of this information to care of prostate cancer patients.
During his Ph.D. training, Dr. Barbieri studied transcriptional targets of p53 family members, gaining extensive expertise in cancer biology and cell and molecular biology techniques.
Dr. Barbieri’s post-doctoral work identifying and characterizing SPOP mutations in prostate cancer led to several recent publications and recognition by the Prostate Cancer Foundation, Urology Care Foundation, and AACR.
He is currently PI on several funded projects investigating molecular subclasses of prostate cancer.
Dr. Barbieri’s goal for this SPORE is to utilize the considerable experience and resources his group has developed regarding SPOP mutant prostate cancer to define the susceptibility of this subtype to DNA damaging therapies and extend this concept to clinical trials. Both Dr. Barbieri’s clinical activities focused on the care of prostate cancer patients and his laboratory focused on models of SPOP mutant prostate cancer will facilitate achieving this goal.